FluiDx-AD Project

• FluiDx-AD is set to improve Alzheimer’s disease diagnosis and management – By developing minimally invasive, cost-effective tests using saliva and blood, FluiDx-AD aims to improve early detection and patient management.
  
  

• Early detection is key – FluiDx-AD’s innovative diagnostics will identify Alzheimer’s disease in its early stages, potentially reducing diagnosis times from years to months.
  
  

• Bridging the gap between research and clinical practice – With leading hospitals, patient organisations & SMEs on board, FluiDx-AD will ensure new tests move from the lab to real-world application.
  
  

• Supporting safer treatment options – With the rise of new Alzheimer’s disease therapies, FluiDx-AD’s tests will help assess treatment eligibility & monitor potential side effects like ARIA.
  
  

• Backed by the EU & top research institutions – FluiDx-AD is a Horizon Europe-funded initiative bringing together experts across Europe to advance precision diagnostics for Alzheimer’s disease.
  
  

Link: FluiDx-AD – A novel test trio to detect peptide biomarkers in saliva and blood for enhanced diagnosis and management of Alzheimer's disease